Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
Kymera Therapeutics is asking shareholders to vote at its virtual 2026 annual meeting on June 24, 2026. Holders of 82,257,588 common shares as of April 27, 2026 may participate online.
Shareholders will elect four Class III directors to serve until 2029, cast a non-binding advisory “Say‑on‑Pay” vote on executive compensation, and vote on ratifying Ernst & Young LLP as independent auditor for 2026. The board recommends voting “FOR” all three proposals.
The proxy outlines a staggered board structure, committee independence, and a clawback policy, and describes Kymera’s performance-based pay philosophy, including a 125% corporate bonus funding factor for 2025 tied to pipeline progress, strategic partnerships, and a year‑end cash balance of about $1.6 billion.
Kymera Therapeutics director Bruce Booth reported option exercises and related share sales in Kymera Therapeutics, Inc. common stock. On April 22, 2026 he exercised options for 259 shares at $20.00 per share and 5,641 shares at $14.18 per share, then sold 5,900 shares in open‑market transactions at a weighted average price of about $89.96 per share, leaving no directly owned shares.
Entities associated with Atlas Venture made additional small sales of 12 and 88 shares at $90.08 per share. After these trades, Atlas Venture Fund X, L.P. held 674,944 shares and Atlas Venture Opportunity Fund I, L.P. held 3,899,829 shares, with Booth disclaiming Section 16 beneficial ownership except to any pecuniary interest. The filing notes these sales were made under pre‑arranged Rule 10b5‑1 trading plans adopted in December 2025.
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported a mix of option exercises and a small stock sale. On April 22, 2026, he exercised stock options for a total of 300 shares of common stock at exercise prices of $43.50 and $30.17 per share, then made an open-market sale of 300 shares at $90.00 per share. After these transactions, he directly held 61,202 shares of Kymera common stock. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, indicating they were scheduled in advance rather than timed discretionarily.
KYMR notice: Section 144 filings report proposed sales of Common Stock by several holders. Examples include Atlas Venture Fund X, L.P. proposing 71,814 shares on 03/02/2026 for $6,472,674.74 and other smaller dispositions in March–April 2026.
KYMR submitted Form 144 notices reporting multiple proposed sales of Common Stock by affiliated holders. The excerpt lists several transactions, including Atlas Venture Fund X, L.P.'s proposed sale of 71,814 shares on 03/02/2026 and smaller sales by Atlas Venture Opportunity Fund I and Bruce Booth on 03/02/2026, 04/14/2026, and 04/15/2026.
KYMR affiliate reported proposed and recent sales of Common Stock. The filing lists an exercise of 300 shares on 04/22/2026 and multiple 10b5-1 sales between 03/02/2026 and 04/15/2026, including transactions of 91,250 shares for $7,063,733.26.
Kymera Therapeutics, Inc. Chief Business Officer Noah Goodman reported an open-market sale of company stock. On April 14, 2026, he sold 1,347 shares of Kymera common stock at $90.00 per share. After this transaction, Goodman directly holds 50,195.438 shares of common stock.
The filing notes that these transactions were made under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025, indicating the sale was scheduled in advance rather than timed discretionarily.
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported option exercises and related share sales. On April 14–15, 2026, he exercised stock options to acquire a total of 6,551 shares of common stock at exercise prices of $30.17 and $43.50 per share.
On the same dates, he sold 6,551 common shares in open-market transactions at prices around $90.00 to $90.10 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly owned 61,202 Kymera Therapeutics shares.
Kymera Therapeutics director Bruce Booth reported option exercises and share sales in Kymera Therapeutics, Inc. common stock. Booth exercised stock options to acquire 6,359 shares at an exercise price of $14.18 per share, then sold 6,359 directly held shares in open-market trades around $90 per share.
Additional sales of 2,750 shares and 385 shares were made by investment funds Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., with which Booth is associated and where he disclaims Section 16 beneficial ownership except for any pecuniary interest. These transactions, totaling 9,494 shares sold, were executed under Rule 10b5-1 trading plans adopted in December 2025, indicating they were pre-arranged rather than timed discretionarily.
KYMR and certain holders submitted Form 144 to notify proposed sales of Common Stock. The filing lists specific proposed sales by Atlas Venture Fund X (71,814 shares for $6,472,674.74), Atlas Venture Opportunity Fund I (10,052 shares for $905,997.81), and Bruce Booth (4,159 shares for $374,199.56), with a filing reference date of 04/15/2026.